#DoxyPEP prevented STIs in gay men, but Jenell Stewart reports this was not the case for cisgender women. May be due to differing drug concentrations in vaginal/cervical vs rectal tissue or low adherence. We’ve seen something similar with TDF/FTC PrEP for women. #CROI2023
Here's my report for @eBARnews on the #doxyPEP study in gay & bi men & trans women presented last year.
ebar.com/story.php?3193…
Jennell Stewart (@drjenellstewart): "Stigma is a major issue regarding sexual health, STIs & HIV. It needs to be addressed if were going to make progress in this area." #DoxyPEP presenters at #CROI2023
Good report from @benryanwriter. (Clearly he focused on this as a first #CROI2023 report while I focused on the Dusseldorf Patient.)

Here’s my report for @aidsmap aidsmap.com/news/feb-2023/…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Liz Highleyman

Liz Highleyman Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @LizHighleyman

Feb 22
It's been a long day at #CROI2023, but I'll attempt to live-tweet @MichaelPelusoMD's presentation on #longCOVID. Though mainly an #HIV meeting, CROI also includes the hot infectious diseases of the day. (Thanks Dr Peluso for providing advance slides & permission to share.) 1/ Image
@MichaelPelusoMD .@MichaelPelusoMD & colleagues' SCOPE cohort at @UCSF + international collaborators have now studied more than 700 people with #longCOVID 2/ Image
.@MichaelPelusoMD at #CROI2023: #LongCOVID is many things. 3/ Image
Read 23 tweets
Feb 21
.@MonicaGandhi9 presents promising results from @ZSFGCare @SF_DPH SPLASH program to treat disadvantaged safety-net population at Ward 86 with long-acting injectable antiretrovirals -- even if not virally suppression at outset. #CROI2023 1/ Image
Among those without viral suppression (ie, outside FDA indication for Cabenuva), 55 out of 57 achieved undetectable VL after starting monthly injectables -- comparable to rates seen in pivotal clinical trials. 2/ Image
.@MonicaGandhi9: We need innovations in #HIV treatment for this population. "If used creatively & used boldly, long-acting ART could really make a dent in the HIV epidemic." #CROI2023 3/
Read 6 tweets
Feb 21
Susan Buchbinder (@SF_DPH @BridgeHIV) & Larry Corey (@fredhutch) discuss where we are with #HIV vaccines after Mosaico trial failure. Buchbinder says it's "a very vibrant time" in HIV vaccine research. Corey adds that the science is "terrifically fascinating." #CROI2023 1/ Image
I think his characterization of sophisticated novel HIV vaccine approaches as "a little bit more complicated" & going to "take a little more time" is an underestimate. It's certainly a lot more complicated to explain versus traditional vaccines! 2/
poz.com/article/hiv-va…
But it's good to hear they're optimistic. I've been kind of discouraged about the #HIV vaccine research field since doing this @pozmagazine overview a couple years ago. #CROI2023 3/
poz.com/article/shot-d…
Read 4 tweets
Feb 21
.@profchloeorkin presents disturbing data on #monkeypox/#mpox among HIV+ people w/low CD4 counts. High rate of complications & death. Concludes mpox is an opportunistic pathogen & severe necrotizing form is an AIDS-defining condition, @CDCgov & @WHO should include. #CROI2023 1/ ImageImage
Concern about IRIS for people who start antiretrovirals once severe symptoms are underway -- can make worse. But unclear whether ART would be beneficial if started at beginning of mpox symptoms. 2/
The good news is no #HIV+ people with a CD4 count >200 died, nor did anyone who received #mpox vaccine. 3/
Read 9 tweets
Dec 31, 2022
Since it's that time of year, here's a selection of some of my favorite articles I wrote in 2022.
My main focus is #HIV. Here, for @pozmagazine, a look at advances in antiretroviral treatment & prospects for a functional cure. 1/
poz.com/article/long-w…
For @aidsmap, a report from #AIDS2022 about a 5th person cured of #HIV after a stem cell transplant. (The 4th such case was reported earlier in the year at #CROI2022/#CROI22). 2/

aidsmap.com/news/aug-2022/…
I did a couple articles on #HIV vaccines, which remain elusive. But mRNA technology is advancing that effort & also showing promise for cancer vaccines. 3/

cancerhealth.com/article/mrna-r…
Read 10 tweets
Dec 30, 2022
This psychologizing of people with different risk tolerance is tedious. Mask proponents can't grasp that we've seen evidence over 3 years that masking doesn't appear to affect case trajectories much at the community level & decided marginal benefits aren't worth the drawbacks. 1/
.@ianmSC can be a gadfly, but he's posted many graphs like this showing that cities & countries with mask mandates or strong masking culture have case trajectories similar to those of places that don't. 2/

If masks had a substantial protective effect at the community level, it should be clearly apparent by now, like the substantial effect of vaccines on COVID hospitalization & deaths. 3/
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(